Abstract: DECELLULARIZED TENON HYDROGEL COMPOSITION, METHOD OF PREPARATION AND APPLICATION THEREOF ABSTRACT 5 The present disclosure relates to decellularized hydrogel composition comprising decellularized tenon’s capsule matrix, growth media composition and cell(s). The decellularized tenon hydrogel composition is effective in managing ophthalmological condition without exhibiting any side effect. The decellularized tenon hydrogel composition is non-toxic and does not elicit immune response while managing ophthalmological condition. 10 FIGURE 1
DESC:AS FILED PDF DOCUMENTS ,CLAIMS:AS FILED PDF DOCUMENTS
| # | Name | Date |
|---|---|---|
| 1 | 202241039927-STATEMENT OF UNDERTAKING (FORM 3) [12-07-2022(online)].pdf | 2022-07-12 |
| 2 | 202241039927-PROVISIONAL SPECIFICATION [12-07-2022(online)].pdf | 2022-07-12 |
| 3 | 202241039927-FORM 1 [12-07-2022(online)].pdf | 2022-07-12 |
| 4 | 202241039927-DRAWINGS [12-07-2022(online)].pdf | 2022-07-12 |
| 5 | 202241039927-DECLARATION OF INVENTORSHIP (FORM 5) [12-07-2022(online)].pdf | 2022-07-12 |
| 6 | 202241039927-FORM-26 [05-09-2022(online)].pdf | 2022-09-05 |
| 7 | 202241039927-Proof of Right [02-11-2022(online)].pdf | 2022-11-02 |
| 8 | 202241039927-PostDating-(11-07-2023)-(E-6-233-2023-CHE).pdf | 2023-07-11 |
| 9 | 202241039927-APPLICATIONFORPOSTDATING [11-07-2023(online)].pdf | 2023-07-11 |
| 10 | 202241039927-DRAWING [12-01-2024(online)].pdf | 2024-01-12 |
| 11 | 202241039927-CORRESPONDENCE-OTHERS [12-01-2024(online)].pdf | 2024-01-12 |
| 12 | 202241039927-COMPLETE SPECIFICATION [12-01-2024(online)].pdf | 2024-01-12 |
| 13 | 202241039927-FORM 18 [24-01-2025(online)].pdf | 2025-01-24 |